• Athens - Greece
  • +30 693 94 34 029 +30 690 77 33 751
  • Contact us
image description

Cancer Diagnosis – What to do?Is there any chance of recovery?

Cancer in 2018: more than 18 million cases and 9.6 million deaths. Every fifth man and every sixth woman will get cancer at any stage of life. This is reported today from the World Health Organization, based on the figures for 2018. However, some types of cancer are curable, others can be converted into chronic disease and advances in medicine make it possible to prolong the lives of many people with cancer.
image description



- a drug that can not only stop the irreversible development of cancer and metastases, but also can completely fight and cure some forms of cancer. We present you a revolutionary discovery in medicine and nanobiotechnology - it is a broad-spectrum oncological (antitumor) drug that has no analogues in the world - Lipoplatin or Nanoplatin (also known as liposomal cisplatin).
image description



developed by Regulon, is a unique liposomal oncological drug capable of destroying cancer and the smallest metastases without surgery and no side effects.

About Regulon

Regulon, Inc (Regulon) is a biopharmaceutical company committed to the discovery, development, testing, and commercialization of low toxicity anti-cancer pharmaceuticals based on a unique patented encapsulation technology. The company was founded in 1997 in Silicon Valley, California (USA) and is based in Athens, Greece & with operations in Europe and Asia. Our objective is to develop a broad range of drugs to be used in cancer therapy. We believe we have achieved a breakthrough in the development of a unique liposome encapsulation technology. Regulon engages in the discovery and development of nanopharmaceutics in oncology based on liposome encapsulation platform technology. Its products include Lipoplatin, a liposomally encapsulated cisplatin for various cancer indications, including non-small cell lung cancer and pancreatic cancer. Regulon's unique liposome encapsulation technology applicable to drugs, small molecules, peptides, proteins and viruses, significantly reduces the side effects of chemotherapy known to exacerbate the quality of life (QOL) of cancer patients. The firm has successfully applied this technology to encapsulate two members of the platinum family of anticancer drugs: cisplatin and oxaliplatin.

Lipoplatin brought a revolution in classical chemotherapy because it does not affect healthy tissue after intravenous administration, concentrating in tumor tissue and metastases.

High Standards - Patients are treated in the best clinics of Greece that meet the highest international and European standards on the basis of its own developments and technologies agreed and approved by the EMA (European Medical Association) and the Ministry of Health of Greece.

Clinical researches - They showed extremely low toxicity with an improved therapeutic effect (index).

Results of treatment - The drug developed by the company has anti-cancer efficacy more than 10-50 times higher than "traditional" drugs and treatment methods.

Years of research


No Side Effects


Without surgery


Of patients


image description

New treatment results for malignant neoplasms

Latest news update

Lipoplatin RT: Clinical studies pioneered by Professor Koukourakis at the University Hospital of Alexandroupolis using fractions of radiation therapy (RT) in combination with Lipoplatin against gastric cancer patients have shown up to 80% complete response. Lipoplatin weekly 120 mg/m2 (D1). 5-FU weekly 400 mg/m2 (D1). Radiotherapy at 3.5-Gy fractions on Days 2,3,4.

RESULTS: 4 of 5 patients had complete response after 5 weekly cycles (Koukourakis et al, 2010 Int J Radiation Oncology Biol Phys 78, 150-155).

Phase I-II trial of Lipoplatin (dose escalation) and Gemcitabine as a second-line chemotherapy in patients with advanced pancreatic cancer (24 patients)

Stathopoulos et al, Oncol Rep 15, 1201-1204 (2006)

Partial response in 2/24 patients (8.3%), disease stability in 14 patients (58.3%) for a median duration of 3 months (range 2-7 months) and clinical benefit in 8 patients (33.3%).

Phase I trial of Lipoplatin (dose escalation) and Gemcitabine as a second-line chemotherapy in patients with non small cell lung carcinoma (13 patients)

Froudarakis et al, Cancer 113:2752-60 (2008)

The first dose escalation and pharmacokinetic study reported for the comb...

In 2012 Dr. Stathopoulos published a study on the application of Lipoplatin on patients with renal dysfunction. Usually patients with creatinine levels of 1.6 to 4.0 mg/dl or with a Glomerular Filtration Rate (GFR) of less than 60 ml/min cannot be treated with chemotherapy. In all oncology protocols one of the standard exclusion criteria is renal insufficiency (patients with creatinine levels above 1.6 mg/dl are excluded from all oncology protocols).

In the Stathopoulos  study 42 patients mainly with lung and bladder cancers with renal insufficiency (creatinine levels 1.6 to 4.0 mg/ dl) were treated with Lipoplatin monotherapy or with its combination with gemcitabine, paclitaxel, or 5-fluor...